Inhibition of UDP/P2Y6 purinergic signaling prevents phagocytosis of viable neurons by activated microglia in vitro and in vivo.
Microglia activated through Toll-like receptor (TLR)-2 or -4 can cause neuronal death by phagocytosing otherwise-viable neurons-a form of cell death called "phagoptosis." UDP release from neurons has been shown to provoke microglial phagocytosis of neurons via microglial P2Y6 receptors, but whether inhibition of this process affects neuronal survival is unknown. We tested here whether inhibition of P2Y6 signaling could prevent neuronal death in inflammatory conditions, and whether UDP signaling can induce phagoptosis of stressed but viable neurons. We find that delayed neuronal loss and death in mixed neuronal/glial cultures induced by the TLR ligands lipopolysaccharide (LPS) or lipoteichoic acid was prevented by: apyrase (to degrade nucleotides), Reactive Blue 2 (to inhibit purinergic signaling), or MRS2578 (to specifically block P2Y6 receptors). In each case, inflammatory activation of microglia was not affected, and the rescued neurons remained viable for at least 7 days. Blocking P2Y6 receptors with MRS2578 also prevented phagoptosis of neurons induced by 250 nM amyloid beta 1-42, 5 μM peroxynitrite, or 50 μM 3-morpholinosydnonimine (which releases reactive oxygen and nitrogen species). Furthermore, the P2Y6 receptor agonist UDP by itself was sufficient to stimulate microglial phagocytosis and to induce rapid neuronal loss that was prevented by eliminating microglia or inhibiting phagocytosis. In vivo, injection of LPS into rat striatum induced microglial activation and delayed neuronal loss and blocking P2Y6 receptors with MRS2578 prevented this neuronal loss. Thus, blocking UDP/P2Y6 signaling is sufficient to prevent neuronal loss and death induced by a wide range of stimuli that activate microglial phagocytosis of neurons.
Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.
Jonas J
JJ
Neher
Urte
U
Neniskyte
Tamara
T
Hornik
Guy C
GC
Brown
D016229:Amyloid beta-Peptides / Q000633:toxicity; D000818:Animals; D001081:Apyrase / Q000494:pharmacology; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000187:drug effects / Q000276:immunology; D017879:Isothiocyanates / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000633:toxicity; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000502:physiology*; D009474:Neurons / Q000187:drug effects / Q000276:immunology*; D018696:Neuroprotective Agents / Q000494:pharmacology; D010446:Peptide Fragments / Q000633:toxicity; D030421:Peroxynitrous Acid / Q000633:toxicity; D010587:Phagocytosis / Q000187:drug effects / Q000502:physiology*; D058919:Purinergic P2 Receptor Antagonists / Q000494:pharmacology; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013682:Teichoic Acids / Q000633:toxicity; D013890:Thiourea / Q000031:analogs & derivatives / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology; D014530:Uridine Diphosphate / Q000378:metabolism*
D016229:Amyloid beta-Peptides; D017879:Isothiocyanates; D008070:Lipopolysaccharides; C541384:N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D013682:Teichoic Acids; D014227:Triazines; C075222:amyloid beta-protein (1-42); C099845:purinoceptor P2Y6; D030421:Peroxynitrous Acid; C009900:lipoteichoic acid; D014530:Uridine Diphosphate; C012842:Cibacron Blue F 3GA; D001081:Apyrase; D013890:Thiourea
P2Y6 receptor; amyloid β; neuroinflammation; phagoptosis; uridine diphosphate